High-Dose chemo and stem cell transplant shows promise for HIV lymphoma patients
NCT ID NCT00641381
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested whether high-dose chemotherapy followed by a stem cell transplant is safe and feasible for 25 people with HIV who also have lymphoma. The goal was to see how well the body recovers and to monitor side effects. Results could point to a new treatment path for this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- high-dose chemotherapy (carmustine, etoposide, cyclophosphamide) followed by autologous stem cell transplant
- What this could lead to
- If successful, this approach could offer a treatment option for people with HIV who develop lymphoma, potentially improving survival.
- What could go wrong
- This is a small, early-phase trial focused on safety, so it's too soon to know if it works. High-dose chemotherapy has serious side effects, and the results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010-3000, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill boost Chemotherapy's punch against lymphoma?